17 analysts have shared their evaluations of Veeva Sys VEEV during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 9 | 2 | 1 | 0 |
| Last 30D | 0 | 0 | 0 | 1 | 0 |
| 1M Ago | 5 | 6 | 2 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $241.06, a high estimate of $270.00, and a low estimate of $203.00. This current average reflects an increase of 12.03% from the previous average price target of $215.18.
Interpreting Analyst Ratings: A Closer Look
In examining recent analyst actions, we gain insights into how financial experts perceive Veeva Sys. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Craig Hettenbach | Morgan Stanley | Raises | Underweight | $210.00 | $160.00 |
| Scott Schoenhaus | Keybanc | Raises | Overweight | $250.00 | $232.00 |
| David Windley | Jefferies | Raises | Buy | $270.00 | $225.00 |
| Joe Vruwink | Baird | Raises | Outperform | $251.00 | $245.00 |
| Tyler Radke | Citigroup | Raises | Buy | $264.00 | $240.00 |
| Gabriela Borges | Goldman Sachs | Raises | Buy | $248.00 | $219.00 |
| David Grossman | Stifel | Raises | Buy | $250.00 | $205.00 |
| Jailendra Singh | Truist Securities | Raises | Hold | $203.00 | $187.00 |
| Ryan MacDonald | Needham | Raises | Buy | $260.00 | $220.00 |
| Saket Kalia | Barclays | Raises | Overweight | $245.00 | $240.00 |
| Brent Bracelin | Piper Sandler | Raises | Overweight | $245.00 | $220.00 |
| Karl Keirstead | UBS | Raises | Neutral | $235.00 | $185.00 |
| Saket Kalia | Barclays | Raises | Overweight | $240.00 | $220.00 |
| Ken Wong | Oppenheimer | Maintains | Outperform | $225.00 | $225.00 |
| Scott Schoenhaus | Keybanc | Raises | Overweight | $232.00 | $210.00 |
| Rishi Jaluria | RBC Capital | Raises | Outperform | $250.00 | $225.00 |
| Brent Bracelin | Piper Sandler | Raises | Overweight | $220.00 | $200.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Veeva Sys. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Veeva Sys compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Veeva Sys's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Veeva Sys's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Veeva Sys analyst ratings.
All You Need to Know About Veeva Sys
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Veeva Sys's Financial Performance
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Veeva Sys's remarkable performance in 3 months is evident. As of 31 January, 2024, the company achieved an impressive revenue growth rate of 2.29%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Veeva Sys's net margin excels beyond industry benchmarks, reaching 23.37%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Veeva Sys's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.27% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Veeva Sys's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.65% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Veeva Sys adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
